• IX Biopharma shareholders authorized share issuance at the October 16, 2026, annual meeting, capped at 100% of issued shares.
• Non-pro-rata issuance authority was limited to 50% of issued shares.
• Share issuance under the iX Employee Share Option Scheme and iX Performance Share Plan was authorized, subject to a combined 15% cap.
• Eddy Lee Yip Hang and Patrick Donald Davies were approved for reappointment as directors.
• Directors' statement and audited accounts for the year ended June 30, 2026, adopted; BDO LLP's reappointment as auditor approved.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IX Biopharma Ltd. published the original content used to generate this news brief via Singapore Exchange Limited (SGX) (Ref. ID: AAMERIRLHUN0RP4X) on November 11, 2026, and is solely responsible for the information contained therein.